To do so, we developed a new model training paradigm in which we compared SNV fragments (true label) from plasma samples with high TF (range 8-37%, Supplementary Table 1) to SNV fragments containing sequencing errors drawn from controls without known cancer. The gene discussed is TF; the disease is cancer.